-
CHPA advocates restoring OTC eligibility under flexible spending accounts
WASHINGTON — The Consumer Healthcare Products Association on Friday submitted a letter to U.S. Treasury Secretary Jacob Lew, thanking the Administration for its recent efforts to enhance flexible savings arrangements’ benefits, the association announced. The association is asking the Administration to take a further step and support restoring over-the-counter medicines’ eligibility under tax-preferred accounts including FSAs and health savings accounts.
-
Actavis seeks approval for generic testosterone-replacement drug
DUBLIN — Drug maker Actavis hopes to become the first to market with a generic version of a topical testosterone replacement drug marketed by Eli Lilly, Actavis said.
The generic drug maker it filed with the Food and Drug Administration for approval of testosterone topical solution in the 30-mg-per-1.5 mL strength, a generic version of Lilly's Axiron. The drug is used as a replacement therapy for deficient or absent testosterone.